| 摘要 |
1361574 4-(4-Biphenylyl)-1-butanol; biphenylyl intermediates DR KARL THOMAE GmbH 13 Oct 1972 [15 Oct 1971] 47442/72 Heading C2C The invention comprises 4-(4-biphenylyl)-1- butanol. It may be prepared by the following methods: (a) reduction of a compound of Formula II in which B represents a hydroxy, alkoxy, aralkoxy, aryloxy or acyloxy group or a halogen atom, e.g. by a complex hydride or catalytically activated hydrogen or if B is halogen by sodium borohydride; (b) reduction of a compound of Formula II above or a compound of Formula III in which A is a hydroxymethylene or keto group, Y and Z are hydrogen or together represent a double bond and B<SP>1</SP> represents a hydroxyalkoxy, aralkoxy or aryloxy group or (if A is a keto group) an acyloxy group or (if A is a keto group and Y and Z represent a double bond) a halogen atom by hydrogenation in the presence of a catalyst, e.g. copper chromium oxide or zinc chromium oxide, (c) from compounds of Formula IV or Formula IVa by hydrogenation in the presence of a catalyst, e.g. noble metal catalysts, copper chromium oxide or zinc chromium oxide; (d) reaction of a Grignard reagent of Formula V with ethylene oxide; (e) hydrogenation of 4-(4- biphenylyl)-3-buten-1-ol in the presence of a catalyst, e.g. Raney nickel or Raney cobalt; (f) treatment of 3-(4-biphenylyl)<SP>1</SP>-tetrohydrofuran with hydrogen in the presence of an acid and a catalyst, e.g. palladium on charcoal. The 1-(4-biphenylyl)-1,4-butanediol used as starting material in method (c) above may be prepared by reacting biphenyl with ethylene oxide in the presence of aluminium chloride to give 4-(4- biphenylyl)-4-oxo-butyric acid which is then treated with lithium aluminium hydride to give the required compound. 4-(4-Biphenylyl)-1-butanol is used as the active ingredient in pharmaceutical compositions which may also contain conventional diluents and extenders and may be administered in the form of tablets, pills, gelatin capsules or suppositories. |
